cognition

Three-month stability of the CogState brief battery in healthy older adults, mild cognitive impairment, and Alzheimer’s disease: results from the Australian Imaging, Biomarkers, and Lifestyle-rate of change substudy (AIBL-ROCS)

Authors: Yen Ying Lim, Judith Jaeger, Karra Harrington, Tim Ashwood, Kathryn A Ellis, Albrecht Stöffler, Cassandra Szoeke, Rebecca Lachovitzki, Ralph N Martins, Victor L Villemagne, Ashley Bush, Colin L Masters, Christopher C Rowe, David Ames, David Darby, Paul Maruff

Journal: Archives of Clinical Neuropsychology

Year Published: 2013

Large prospective studies of Alzheimer’s disease (AD) have sought to understand the pathological evolution of AD and factors that may influence the rate of disease progression. Estimates of rates of cognitive change are available for 12 […]

A randomized, double-blind, placebo-controlled crossover study of α4β 2* nicotinic acetylcholine receptor agonist AZD1446 (TC-6683) in adults with attention-deficit/hyperactivity disorder

Authors: Aurelija Jucaite, John Öhd, Alexandra S Potter, Judith Jaeger, Pär Karlsson, Kristin Hannesdottir, Emma Boström, Paul A Newhouse, Björn Paulsson

Journal: Psychopharmacology

Year Published: 2014

Rationale: Stimulation of nicotinic cholinergic systems has been shown to alleviate ADHD symptoms and to improve cognitive performance. AZD1446 is a selective α4β2* nicotinic acetylcholine receptor agonist with potential effect on the symptoms of ADHD. Objectives: […]

Reliability and validity of the CogState battery Chinese language version in schizophrenia

Authors: Na Zhong, Haifeng Jiang, Jin Wu, Hong Chen, Shuxing Lin, Yan Zhao, Jiang Du, Xiancang Ma, Ce Chen, Chengge Gao, Kenji Hashimoto, Min Zhao

Journal: Public Library of Science One

Year Published: 2013

Background: Cognitive impairment in patients with schizophrenia is a core symptom of this disease. The computerized CogState Battery (CSB) has been used to detect seven of the most common cognitive domains in schizophrenia. The aim of […]

A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer’s disease

Authors: Richard A Grove, Conn M Harrington, Andreas Mahler, Isabel Beresford, Paul Maruff, Martin T Lowy, Andrew P Nicholls, Rebecca L Boardley, Alienor C Berges, Pradeep J Nathan, Joseph P Horrigan

Journal: Current Alzheimer Research

Year Published: 2014

Introduction: Histaminergic H3 receptors may play a role in modulating cholinergic and monoaminergic neurotransmission. This Phase II study evaluated the efficacy and safety of GSK239512, a highly potent, brain penetrant H3 receptor antagonist as monotherapy treatment […]

Prospective associations between dietary patterns and cognitive performance during adolescence

Authors: Anett Nyaradi, Jonathan K Foster, Siobhan Hickling, Jianghong Li, Gina L Ambrosini, Angela Jacques, Wendy H Oddy

Journal: Journal of Child Psychology and Psychiatry and Allied Disciplines

Year Published: 2014

Background: The aim of the study was to investigate prospective associations between dietary patterns and cognitive performance during adolescence. Methods: Participants were sourced from the Western Australian Pregnancy Cohort (Raine) Study that includes 2868 children born […]

1 19 20 21 22

Back to Publications